<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02126462</url>
  </required_header>
  <id_info>
    <org_study_id>HV-001</org_study_id>
    <secondary_id>602843-2</secondary_id>
    <nct_id>NCT02126462</nct_id>
  </id_info>
  <brief_title>Safety and Immunogenicity of Co-Administered Hookworm Vaccine Candidates Na-GST-1 and Na-APR-1 in Gabonese Adults</brief_title>
  <official_title>Randomized, Controlled, Phase 1 Study to Assess Safety and Immunogenicity of Co-administered Hookworm Vaccine Candidates Na-GST-1 and Na-APR-1 Adjuvanted With Alhydrogel® and Gluco-pyranosylphospho-lipid A in Gabonese Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baylor College of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Baylor College of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Na-GST-1 and Na-APR-1 are proteins expressed during the adult stage of the Necator americanus&#xD;
      hookworm life cycle that are thought to play a role in the parasite's degradation of host&#xD;
      hemoglobin for use as an energy source. Vaccination with recombinant GST-1 or APR-1 has&#xD;
      protected dogs and hamsters from infection in challenge studies. This study will evaluate the&#xD;
      safety and immunogenicity of co-administering Na-GST-1 and Na-APR-1 to healthy Gabonese&#xD;
      adults living in an area of endemic hookworm infection.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Double-blind, randomized, controlled dose-escalation Phase 1 clinical trial in hookworm&#xD;
      exposed adults.&#xD;
&#xD;
      Study site: Centre de Recherches Médicales de Lambaréné Number of participants: 32 in 2&#xD;
      cohorts of 16&#xD;
&#xD;
      Doses of Na-GST-1 to be tested: 30 and 100 μg Doses of Na-APR-1 to be tested: 30 and 100 μg&#xD;
      Dose of GLA-AF: 5 μg per antigen&#xD;
&#xD;
      Cohort 1: 30 μg of each of the two antigens (Na-GST-1/Alhydrogel® and Na-APR-1&#xD;
      (M74)/Alhydrogel®) or hepatitis B vaccine; Cohort 2: 100 μg of each of the two antigens&#xD;
      (Na-GST- 1/Alhydrogel® and Na-APR-1 (M74) /Alhydrogel®) or hepatitis B vaccine.&#xD;
&#xD;
      Randomization: Cohort 1: 30 μg Na-GST-1 + 30 μg Na-APR-1 (M74) (n = 12) versus Hepatitis B&#xD;
      Vaccine/placebo (n = 4) Cohort 2: 100 μg Na-GST-1 + 100 μg Na-APR-1 (M74) (n = 12) versus&#xD;
      Hepatitis B Vaccine + placebo (n = 4)&#xD;
&#xD;
      The cohorts will be enrolled in a staggered fashion with safety data assessed prior to the&#xD;
      Na-GST-1 and Na-APR-1 dose escalation from 30 to 100 µg.&#xD;
&#xD;
      Pre-treatment: Albendazole (400 mg) at least 2 weeks prior to first vaccination&#xD;
&#xD;
      Immunization schedule: Study days 0, 28 and 180 Route: Intramuscular in the deltoid muscle&#xD;
&#xD;
      Study duration: approximately 20 months; each participant will be followed for a total of 12&#xD;
      months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2014</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">February 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Vaccine-related Adverse Events</measure>
    <time_frame>Day 360</time_frame>
    <description>To estimate the frequency of vaccine-related adverse events, graded by severity, for each dose of co-administered Na-GST-1 and Na-APR-1 (M74).&#xD;
The frequency of immediate, systemic, and local injection site adverse events will be summarized. Adverse events will be assessed by study team members at 1 hour post-vaccination as well as 1, 3, 7, 14, and 28 days following each vaccination.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>IgG response to Na-GST-1 and Na-APR-1 (M74)</measure>
    <time_frame>Day 194</time_frame>
    <description>To determine the doses of Na-GST-1 and Na-APR-1 (M74) that generate the highest IgG antibody responses at Day 194, as determined by indirect enzyme-linked immunosorbent assays (ELISA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of antibody response to Na-GST-1 and Na-APR-1 (M74)</measure>
    <time_frame>Day 14, 28, 42, 56, 180, 194, 208, 270, 360</time_frame>
    <description>To assess and compare the duration of antibody responses to Na- GST-1 and Na-APR-1 (M74).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exploratory studies of memory B-cell responses</measure>
    <time_frame>Days 14, 28, 42, 56, 180, 194, 208, 270, 360</time_frame>
    <description>Exploratory studies of memory B-cell responses against the metabolomics changes before and after Na-GST-1 and NA-APR-1 (M74) vaccine antigens.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Hookworm Infection</condition>
  <condition>Hookworm Disease</condition>
  <arm_group>
    <arm_group_label>30 µg Na-GST-1 + 30 µg Na-APR-1 (M74)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>30 µg Na-GST-1/Alhydrogel plus 5 µg GLA-AF co-administered with 30 µg Na-APR-1 (M74)/Alhydrogel plus 5 µg GLA-AF</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hepatitis B vaccine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Hepatitis B vaccine co-administered with saline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>100 µg Na-GST-1 plus 100 µg Na-APR-1 (M74)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100 µg Na-GST-1/Alhydrogel plus 5 µg GLA-AF co-administered with 100 µg Na-APR-1 (M74)/Alhydrogel plus 5 µg GLA-AF</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Na-APR-1 (M74)/Alhydrogel®</intervention_name>
    <arm_group_label>100 µg Na-GST-1 plus 100 µg Na-APR-1 (M74)</arm_group_label>
    <arm_group_label>30 µg Na-GST-1 + 30 µg Na-APR-1 (M74)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Na-GST-1/Alhydrogel®</intervention_name>
    <arm_group_label>100 µg Na-GST-1 plus 100 µg Na-APR-1 (M74)</arm_group_label>
    <arm_group_label>30 µg Na-GST-1 + 30 µg Na-APR-1 (M74)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Hepatitis B vaccine</intervention_name>
    <description>Hepatitis B vaccine co-administered with saline</description>
    <arm_group_label>Hepatitis B vaccine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Males or females between 18 and 50 years, inclusive, who are long-term residents of&#xD;
             Gabon.&#xD;
&#xD;
          -  Good general health as determined by means of the screening procedure.&#xD;
&#xD;
          -  Assumed availability for the duration of the trial (12 months).&#xD;
&#xD;
          -  Willingness to participate in the study as evidenced by signing the informed consent&#xD;
             document.&#xD;
&#xD;
          -  Negative for hookworm during screening, or if found to be infected with hookworm, has&#xD;
             completed a course of three doses of albendazole.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy as determined by a positive urine hCG (if female).&#xD;
&#xD;
          -  Participant unwilling to use reliable contraception up until one month following the&#xD;
             third immunization (if female and not surgically sterile, abstinent or at least 2&#xD;
             years post-menopausal).&#xD;
&#xD;
          -  Currently lactating and breast-feeding (if female).&#xD;
&#xD;
          -  Inability to correctly answer all questions on the informed consent comprehension&#xD;
             questionnaire.&#xD;
&#xD;
          -  Evidence of clinically significant neurologic, cardiac, pulmonary, hepatic,&#xD;
             rheumatologic, autoimmune, diabetes, or renal disease by history, physical&#xD;
             examination, and/or laboratory studies.&#xD;
&#xD;
          -  Known or suspected immunodeficiency.&#xD;
&#xD;
          -  Laboratory evidence of liver disease (alanine aminotransferase [ALT] greater than&#xD;
             1.25-times the upper reference limit).&#xD;
&#xD;
          -  Laboratory evidence of renal disease (serum creatinine greater than 1.25-times the&#xD;
             upper reference limit, or more than trace protein or blood on urine dipstick testing).&#xD;
&#xD;
          -  Laboratory evidence of hematologic disease (absolute leukocyte count &lt;3500/mm3;&#xD;
             absolute leukocyte count &gt;11.0 x 103/mm3; hemoglobin &lt;10.000 g/dl [females] or &lt;12.0&#xD;
             g/dl [males]; or, platelet count &lt;140,000/mm3).&#xD;
&#xD;
          -  Other condition that in the opinion of the investigator would jeopardize the safety or&#xD;
             rights of a volunteer participating in the trial or would render the subject unable to&#xD;
             comply with the protocol.&#xD;
&#xD;
          -  Participation in another investigational vaccine or drug trial within 30 days of&#xD;
             starting this study or for the duration of the study.&#xD;
&#xD;
          -  Volunteer has had medical, occupational, or family problems as a result of alcohol or&#xD;
             illicit drug use during the past 12 months.&#xD;
&#xD;
          -  History of a severe allergic reaction or anaphylaxis.&#xD;
&#xD;
          -  Severe asthma as defined by the need for daily use of inhalers or emergency&#xD;
             room/clinic visit or hospitalization within 6 months of the volunteer's planned first&#xD;
             vaccination in the study.&#xD;
&#xD;
          -  Positive for HCV&#xD;
&#xD;
          -  Positive ELISA for HBsAg.&#xD;
&#xD;
          -  Positive for HIV infection&#xD;
&#xD;
          -  Use of corticosteroids (excluding topical or nasal) or immunosuppressive drugs within&#xD;
             30 days of starting this study or expect to use for the duration of the study.&#xD;
&#xD;
          -  Receipt of a live vaccine within past 4 weeks or a killed vaccine within past 2 weeks&#xD;
             prior to entry into the study.&#xD;
&#xD;
          -  History of a surgical splenectomy.&#xD;
&#xD;
          -  Receipt of blood products within the 6 months prior to entry into the study.&#xD;
&#xD;
          -  Previous receipt of a primary series of any hepatitis B vaccine.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ayola Adegnika, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre de Recherches Medicales de Lambarené</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre de Recherches Médicales de Lambaréné Albert Schweitzer Hospital</name>
      <address>
        <city>Lambaréné</city>
        <zip>BP: 118</zip>
        <country>Gabon</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Gabon</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <study_first_submitted>April 28, 2014</study_first_submitted>
  <study_first_submitted_qc>April 29, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 30, 2014</study_first_posted>
  <last_update_submitted>May 30, 2017</last_update_submitted>
  <last_update_submitted_qc>May 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Baylor College of Medicine</investigator_affiliation>
    <investigator_full_name>Maria Elena Bottazzi PhD</investigator_full_name>
    <investigator_title>Sponsor</investigator_title>
  </responsible_party>
  <keyword>Human Hookworm</keyword>
  <keyword>Necator americanus</keyword>
  <keyword>Hookworm</keyword>
  <keyword>Hookworm Disease</keyword>
  <keyword>Iron-deficiency anemia</keyword>
  <keyword>Soil-transmitted helminth infection</keyword>
  <keyword>Neglected Tropical Disease</keyword>
  <keyword>Na-APR-1</keyword>
  <keyword>Na-GST-1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hookworm Infections</mesh_term>
    <mesh_term>Ancylostomiasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aluminum Hydroxide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

